Osterweis Capital Management’s Akoya BioSciences AKYA Stock Holding History

Osterweis Capital Management’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-126,131	Closed	-$289K	–	339
2024 Q4	$289K	Hold	126,131	–	–	0.01%	125
2024 Q3	$343K	Hold	126,131	–	–	0.02%	120
2024 Q2	$295K	Hold	126,131	–	–	0.02%	122
2024 Q1	$592K	Hold	126,131	–	–	0.03%	106
2023 Q4	$616K	Hold	126,131	–	–	0.04%	107
2023 Q3	$587K	Hold	126,131	–	–	0.04%	105
2023 Q2	$932K	Hold	126,131	–	–	0.06%	104
2023 Q1	$1.03M	Hold	126,131	–	–	0.07%	105
2022 Q4	$1.21M	Hold	126,131	–	–	0.09%	103
2022 Q3	$1.48M	Hold	126,131	–	–	0.11%	104
2022 Q2	$1.62M	Hold	126,131	–	–	0.12%	102
2022 Q1	$1.39M	Hold	126,131	–	–	0.08%	113
2021 Q4	$1.93M	Sell	126,131 -14,557	-10%	-$190K	0.1%	107
2021 Q3	$1.96M	Hold	140,688	–	–	0.11%	105
2021 Q2	$2.72M	Buy	+140,688	New	+$2.9M	0.14%	109

Other funds holding AKYA

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCA

Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return

Osterweis Capital Management's AKYA Position: Q1 2025 in Review

Osterweis Capital Management sold out of Akoya BioSciences (AKYA) in Q1 2025, closing a stake of 126,131 shares — an estimated $289K sold.

Osterweis Capital Management first reported a position in AKYA in Q2 2021 and held it in 15 quarters. The position peaked at $2.72M in Q2 2021. 64 funds tracked by Wall St. Rank hold AKYA as of Q1 2025.

Osterweis Capital Management reported no remaining Akoya BioSciences position as of Q1 2025 after selling out during the quarter.
Osterweis Capital Management sold 126,131 Akoya BioSciences shares in Q1 2025, an estimated $289K.
Osterweis Capital Management first reported a position in Akoya BioSciences in Q2 2021 and held it in 15 quarters.
Osterweis Capital Management's Akoya BioSciences position peaked at $2.72M in Q2 2021.
64 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2025.

Based on Osterweis Capital Management's 13F filing for Q1 2025, filed 14 May 2025.